
OrthoPediatrics (KIDS) Stock Forecast & Price Target
OrthoPediatrics (KIDS) Analyst Ratings
Bulls say
OrthoPediatrics Corp demonstrated a positive financial trajectory with a 50 basis points year-over-year increase in gross margin, attributed to lower international set sales and 7D placements, while the adjusted EBITDA margin rose by 280 basis points. The Trauma & Deformity sales exhibiting a growth of 17.3% to $44.1 million, and strong performance in OPSB with over 20% growth in 3Q25, reflect the firm's solid positioning in the pediatric orthopedic market. Additionally, management's outlook suggests that as revenue continues to grow, improvements in operating leverage and cash flow are anticipated, further supported by new product introductions that may enhance margins.
Bears say
OrthoPediatrics Corp is experiencing a concerning slowdown in revenue growth, evidenced by a decline from 15.7% in Q2 to 12.2% in Q3 of 2025, which raises concerns about the company's ability to maintain momentum in a competitive market. Additionally, the company's guidance for FY25 has been lowered to $233.5M-$234.5M, indicating potential challenges in achieving anticipated financial performance, particularly as cash burn exceeds expectations. Bear case scenarios suggest that issues such as declining productivity among distributors and disappointing sales from new products could further exacerbate margin pressures and cash flow constraints.
This aggregate rating is based on analysts' research of OrthoPediatrics and is not a guaranteed prediction by Public.com or investment advice.
OrthoPediatrics (KIDS) Analyst Forecast & Price Prediction
Start investing in OrthoPediatrics (KIDS)
Order type
Buy in
Order amount
Est. shares
0 shares